Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia: An Overview of Systematic Reviews

Table 4

Main meaningful outcome comparison in included reviews.

Author (y)	Type of patients	Intervention	Outcome(s)
			OS	DFS	RFS	TRM	RR	Survival from relapse	Death rate	Relapse or death rate
Li (2019) [27]	Patients with intermediate-risk AML in CR1	Allo-SCT	HR = 0.84(0.73–0.97)		HR = 0.82(0.73–0.92)	HR = 4.16(3.37–5.15)	HR = 0.53(0.42–0.66)
Li (2015) [26]	Patients with intermediate-risk AML in CR1	Allo-SCT	HR = 0.43(0.22–0.84)		HR = 0.68(0.48–0.95)	HR = 3.09(1.38–6.92)	HR = 0.58(0.45–0.75)
Ma (2015) [25]	FLT3/ITD AML patients	Allo-SCT	OR = 2.88(2.04–4.05)	OR = 2.84(1.89–4.25)			OR = 0.09(0.05–0.18)
Koreth (2009) [31]	AML patients in CR1	Allo-SCT	HR = 0.90(0.82–0.97)		HR = 0.80(0.74–0.86)
Jing (2010) [29]	AML patients in CR1	Allo-SCT	HR = 1.05(0.91–1.21)	HR = 0.89(0.80–0.98)		RR = 1.90(1.34–2.70)	RR = 0.79(0.72–0.87)	HR = 2.09(1.41–3.08)
Koreth (2009) [31]	AML patients in CR1	Allo-SCT	HR = 0.90(0.82–0.97)		HR = 0.80(0.74–0.86)
Levi (2004) [34]	AML patients in CR1	ABMT							RR = 0.94(0.84–1.09)	RR = 0.85(0.75–0.97)
Nathan (2004) [33]	Adult patients with AML	ABMT	1.01(0.89–1.15)	1.24(1.06–1.44)		OR = 2.63(1.60–4.32)
Levi (2004) [34]	AML patients in CR1	ABMT						RR = 0.94(0.84–1.09)	RR = 0.85(0.75–0.97)